Brookline Capital Markets Comments on NTLA FY2027 Earnings

Intellia Therapeutics, Inc. (NASDAQ:NTLA) – Brookline Capital Markets decreased their FY2027 earnings estimates for Intellia Therapeutics in a report issued on Monday, May 11th. Brookline Capital Markets analyst L. Cann now anticipates that the company will post earnings per share of $12.95 for the year, down from their prior forecast of $12.98. The consensus estimate for Intellia Therapeutics’ current full-year earnings is ($3.50) per share.

Other research analysts also recently issued research reports about the company. The Goldman Sachs Group upped their price objective on Intellia Therapeutics from $8.00 to $9.00 and gave the company a “sell” rating in a research note on Tuesday, April 28th. Canaccord Genuity Group lifted their target price on Intellia Therapeutics from $48.00 to $58.00 and gave the stock a “buy” rating in a research note on Tuesday, April 28th. Wall Street Zen upgraded shares of Intellia Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, March 7th. Leerink Partners set a $35.00 price objective on shares of Intellia Therapeutics in a report on Monday, April 27th. Finally, Chardan Capital lifted their price objective on shares of Intellia Therapeutics from $27.00 to $30.00 and gave the stock a “buy” rating in a research report on Monday, April 27th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, ten have given a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $20.55.

Intellia Therapeutics Stock Up 2.3%

NTLA stock opened at $14.42 on Tuesday. The firm has a market cap of $1.74 billion, a PE ratio of -3.77 and a beta of 1.93. The business has a 50 day moving average of $13.67 and a 200-day moving average of $12.22. Intellia Therapeutics has a 12-month low of $6.83 and a 12-month high of $28.25.

Intellia Therapeutics (NASDAQ:NTLA) last issued its quarterly earnings data on Monday, May 11th. The company reported ($0.81) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.91) by $0.10. Intellia Therapeutics had a negative net margin of 609.85% and a negative return on equity of 56.81%. The business had revenue of $15.05 million during the quarter, compared to the consensus estimate of $13.81 million.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in NTLA. Caitong International Asset Management Co. Ltd purchased a new stake in Intellia Therapeutics in the 3rd quarter worth about $30,000. Advisory Services Network LLC bought a new stake in shares of Intellia Therapeutics in the third quarter valued at approximately $33,000. Headlands Technologies LLC purchased a new stake in shares of Intellia Therapeutics during the 2nd quarter valued at approximately $26,000. Comerica Bank lifted its stake in shares of Intellia Therapeutics by 45.8% during the 4th quarter. Comerica Bank now owns 2,869 shares of the company’s stock valued at $26,000 after buying an additional 901 shares in the last quarter. Finally, Danske Bank A S purchased a new position in Intellia Therapeutics in the 3rd quarter valued at approximately $50,000. Hedge funds and other institutional investors own 88.77% of the company’s stock.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.